A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden.
Year: 2009
Type: article
Source: Blood
Institutions: Mayo Clinic, Stanford University, University of California San Diego, Moores Cancer Center, The University of Texas MD Anderson Cancer Center, University of Michigan, Dana-Farber Cancer Institute, Xiamen Innovax Biotech Co., Ltd. (China), Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2579219442